Abstracts - faqs.org

Abstracts

Business, general

Search abstracts:
Abstracts » Business, general

Patents

Article Abstract:

New York's Thinking Media Corp has won a patent for software that tracks responses to Internet ads and commercial Internet sites. Current ways of counting the number of hits a Web icon receives tend to undercount, according to managing dir Owen Davis. The Java applets developed by thinking media actually is embedded in the user's browser, which makes it more accurate than counting software embedded in the website itself. Thinking Media clients include Advance Publications's Conde Nast unit, American Express, Proctor and Gamble, and IBM, according to Davis.

Comment:

Receives a patent for software that tracks responses to Internet ads and commercial Web sites

Author: Chartbrand, Sabra
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
Marketing/Advertising Methods, New Electronic Marketing, Patents & copyrights, Internet server software, Thinking Media

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


First 2 weeks of pro basketball canceled in dispute with union

Article Abstract:

The National Basketball Association (NBA) cancelled the first two weeks of the 1998-99 season due to a labor dispute with its players. The cancellation is the first time in the history of the NBA that any regular season games will have eliminated. Russ Granik, the deputy commissioner of the NBA, announced the cancellation following several hours of talks with players in New York City. Games that were scheduled between November 3 and November 16, 1998 were eliminated. This amounted to 99 games.

Comment:

NBA cancels first two weeks of the 1998-99 season due to a labor dispute with its players

Author: Wise, Mike
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
Company Planning/Goals, Personnel administration, Sports Teams and Clubs, Professional Basketball, National Basketball Association

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Urine test for H.I.V. wins U.S. approval

Article Abstract:

Calypte Biomedical Corporation announced that the Food and Drug Administration (FDA) had given its approval for the marketing of the company's urine HIV test. The test is the first complete diagnostic, urine-based HIV test kit that does not need a blood test confirmation. Urine tests are easier to use and lead to reduced costs for health care providers. It is also a safer product for patients.

Comment:

Announced that the Food and Drug Administration (FDA approved the marketing of the company's urine HIV test

Publisher: The New York Times Company
Publication Name: The New York Times
Subject: Business, general
ISSN: 0362-4331
Year: 1998
Legal/Government Regulation, Laboratory Apparatus and Furniture Manufacturing, Clinical Lab Equipment, Biomedical laboratory equipment, Calypte Biomedical Corporation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Article
Similar abstracts:
  • Abstracts: Strategy and the crystal cycle. The concept of workplace performance and its value to managers
  • Abstracts: Viacom sets sale of cable properties. US West sets cable TV firm buyout. Time Warner sets merger with Turner Broadcasting System
  • Abstracts: A comment on the viability of the allowance for corporate equity. The effect of tax-based savings incentives on government revenue
  • Abstracts: First it was mobile phone calls, now it is mobile everything. The Encyclopedia Britannica learns something its researchers missed
  • Abstracts: Designer puts himself at the heart of marketing. The dying game. Mojo listens to Joe Blow
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.